Mast cells and inflammation

Joint Bone Spine

Volumn 80, Issue 2, 2013, Pages 141-145

  Frenzel, Laurent ^a   Hermine, Olivier ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Inflammation; Mast cell; Mastocytosis; Multiple sclerosis; Rheumatoid arthritis

Indexed keywords

CD40 ANTIGEN; DECTIN 1; IMATINIB; INTERLEUKIN 1BETA; INTERLEUKIN 33; INTERLEUKIN 6; MASITINIB; MIDOSTAURIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ASTHMA; BRONCHOSPASM; CELL ACTIVATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DIARRHEA; EDEMA; HOMEOSTASIS; HUMAN; HUMORAL IMMUNITY; HYPOTENSION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; MAST CELL; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHIC PAIN; NONHUMAN; RASH; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYSTEMIC MASTOCYTOSIS;

ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; MAST CELLS; MASTOCYTOSIS; MULTIPLE SCLEROSIS;

EID: 84875544697     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.08.013     Document Type: Short Survey

References (30)

1. Moon T.C., St Laurent C.D., Morris K.E., et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol 2010, 3:111-128.
2. Zsebo K.M., Williams D.A., Geissler E.N., et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990, 63:213-224.
3. Metcalfe D.D. Mast cells and mastocytosis. Blood 2008, 112:946-956.
4. Sokol H., Georgin-Lavialle S., Grandpeix-Guyodo C., et al. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflamm Bowel Dis 2010, 16:1247-1253.
5. Smith J.H., Butterfield J.H., Pardanani A., et al. Neurologic symptoms and diagnosis in adults with mast cell disease. Clin Neurol Neurosurg 2011, 113:570-574.
6. Moura D.S., Sultan S., Georgin-Lavialle S., et al. Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy. PLoS One 2011, 6:e26375.
7. Dewachter P., Mouton-Faivre C., Hermine O. Mastocytosis is not related to allergic diseases. Allergy 2008, 63:1248.
8. Maurer M., Theoharides T., Granstein R.D., et al. What is the physiological function of mast cells?. Exp Dermatol 2003, 12:886-910.
9. Rao K.N., Brown M.A. Mast cells: multifaceted immune cells with diverse roles in health and disease. Ann N Y Acad Sci 2008, 1143:83-104.
10. Marshall J.S., Jawdat D.M. Mast cells in innate immunity. J Allergy Clin Immunol 2004, 114:21-27.
11. Abraham S.N., St John A.L. Mast cell-orchestrated immunity to pathogens. Nat Rev Immunol 2010, 10:440-452.
12. Galli S.J., Nakae S., Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005, 6:135-142.
13. Piconese S., Gri G., Tripodo C., et al. Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. Blood 2009, 114:2639-2648.
14. Gri G., Piconese S., Frossi B., et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008, 29:771-781.
15. Lu L.F., Lind E.F., Gondek D.C., et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006, 442:997-1002.
16. Lee D.M., Friend D.S., Gurish M.F., et al. A cellular link between autoantibodies and inflammatory arthritis. Science 2002, 297:1689-1692.
17. Hueber A.J., Asquith D.L., Miller A.M., et al. Mast cells express IL17A in rheumatoid arthritis synovium. J Immunol 2010, 184:3336-3340.
18. Shin K., Nigrovic P.A., Crish J., et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009, 182:647-656.
19. Palmer H.S., Kelso E.B., Lockhart J.C., et al. Protease-activated receptor 2 mediates the pro inflammatory effect of synovial mast cells. Arthritis Rheum 2007, 56:3532-3540.
20. Suurmond J., Schuerwegh A.J.M., Toes R.E.M. Anti-citrullinated protein antibodies in rheumatoid arthritis: a functional role of mast cells and basophils?. Ann Rheum Dis 2011, 70:55-58.
21. Rozniecki J.J., Hauser S.L., Stein M., et al. Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 1995, 37:63-66.
22. Secor V.H., Secor W.E., Gutekunst C.A., et al. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000, 191:813-822.
23. Carlson T., Kroenke M., Rao P., et al. The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. J Exp Med 2008, 205:811-823.
24. Walker M.E., Hatfield J.K., Brown M.A., et al. New insights into the role of mast cells in autoimmunity: evidence for a common mechanism of action?. Biochim Biophys Acta 2012, 1822:57-65.
25. Dubreuil P., Letard S., Ciufolini M., et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009, 4:e7258.
26. Paul C., Sans B., Suarez F., et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol 2010, 85:921-925.
27. Tebib J., Mariette X., Bourgeois P., et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Res Ther 2009, 11:R95.
28. Humbert M., de Blay F., Garcia G., et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009, 64:1194-1201.
29. Piette F., Belmin J., Vincent H., et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011, 3:16.
30. Vermersch P., Benrabah R., Schmidt N., et al. Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study. BMC Neurol 2012, 12:36.